ALIVUS LIFE SCIENCES
|
ALIVUS LIFE SCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 45.99 | 39.63 | 38.43 | 38.11 | 34.17 |
| CEPS(Rs) | 52.13 | 44.58 | 42.79 | 41.55 | 37.27 |
| DPS(Rs) | 5.00 | 5.00 | 22.50 | 21.00 | 21.00 |
| Book NAV/Share(Rs) | 270.90 | 229.11 | 189.45 | 173.97 | 167.38 |
| Tax Rate(%) | 24.87 | 25.76 | 25.41 | 25.72 | 25.88 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 30.92 | 28.48 | 29.44 | 29.56 | 28.98 |
| EBIT Margin(%) | 29.35 | 27.39 | 27.64 | 28.96 | 27.89 |
| Pre Tax Margin(%) | 29.14 | 27.29 | 27.57 | 28.93 | 26.58 |
| PAT Margin (%) | 21.89 | 20.26 | 20.56 | 21.49 | 19.70 |
| Cash Profit Margin (%) | 24.81 | 22.79 | 22.90 | 23.43 | 21.48 |
| Performance Ratios | |||||
| ROA(%) | 14.27 | 13.34 | 13.96 | 15.43 | 16.57 |
| ROE(%) | 18.41 | 18.94 | 21.15 | 22.33 | 29.87 |
| ROCE(%) | 24.61 | 25.50 | 28.31 | 30.01 | 42.24 |
| Asset Turnover(x) | 0.65 | 0.66 | 0.68 | 0.72 | 0.84 |
| Sales/Fixed Asset(x) | 1.99 | 2.15 | 2.35 | 2.65 | 3.13 |
| Working Capital/Sales(x) | 1.20 | 1.29 | 1.55 | 1.60 | 1.54 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.47 | 0.43 | 0.38 | 0.32 |
| Receivable days | 144.58 | 132.12 | 125.30 | 124.34 | 111.01 |
| Inventory Days | 96.67 | 102.08 | 101.28 | 94.11 | 88.40 |
| Payable days | 135.45 | 133.54 | 149.95 | 136.29 | 94.72 |
| Valuation Parameters | |||||
| PER(x) | 21.18 | 27.24 | 20.17 | 10.28 | 13.43 |
| PCE(x) | 18.69 | 24.22 | 18.12 | 9.43 | 12.32 |
| Price/Book(x) | 3.60 | 4.71 | 4.09 | 2.25 | 2.74 |
| Yield(%) | 0.51 | 0.46 | 2.90 | 5.36 | 4.58 |
| EV/Net Sales(x) | 4.68 | 5.51 | 4.03 | 2.08 | 2.41 |
| EV/Core EBITDA(x) | 13.94 | 18.35 | 13.40 | 6.69 | 8.10 |
| EV/EBIT(x) | 15.80 | 20.04 | 14.53 | 7.13 | 8.62 |
| EV/CE(x) | 3.59 | 4.67 | 3.94 | 2.10 | 1.80 |
| M Cap / Sales | 4.69 | 5.54 | 4.16 | 2.22 | 2.65 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.91 | 4.54 | 5.64 | 1.79 | 12.63 |
| Core EBITDA Growth(%) | 19.60 | 4.50 | 2.24 | 6.42 | 6.57 |
| EBIT Growth(%) | 15.25 | 3.75 | 0.58 | 6.12 | 6.16 |
| PAT Growth(%) | 16.24 | 3.13 | 0.84 | 11.52 | 19.10 |
| EPS Growth(%) | 16.05 | 3.12 | 0.84 | 11.52 | -90.47 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 4.14 | 4.97 | 4.37 | 2.33 | 2.85 |
| Quick Ratio(x) | 3.12 | 3.53 | 2.85 | 1.74 | 2.16 |
| Interest Cover(x) | 140.86 | 271.97 | 409.34 | 1,150.19 | 21.20 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ALIVUS LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALIVUS LIFE SCIENCES | ₹17,033.0 Cr | -0.3% | -0.9% | 45.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹447,716.0 Cr | 0.1% | -0.6% | 15.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹248,120.0 Cr | -0.6% | 8.7% | 53% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,038.0 Cr | -0.8% | -1.7% | 34.7% | Stock Analytics | |
| CIPLA | ₹110,858.0 Cr | -0.6% | -4.2% | -12.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,828.7 Cr | 2.7% | -0.7% | -12.1% | Stock Analytics | |
ALIVUS LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALIVUS LIFE SCIENCES | -0.3% |
-0.9% |
45.4% |
| SENSEX | -0.6% |
-4.4% |
-8.7% |
You may also like the below Video Courses
